The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Official Title: A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Study ID: NCT04254107
Brief Summary: This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SEA-TGT works to treat solid tumors and lymphomas. The study will have four parts. Part A of the study will find out how much SEA-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SEA-TGT is and if it works to treat solid tumors and lymphomas. Part C will study how well SEA-TGT with sasanlimab works to treat solid tumors. Part D will study how well SEA-TGT with brentuximab vedotin works to treat classical Hodgkin lymphoma (cHL).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Alabama at Birmingham, Birmingham, Alabama, United States
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
City of Hope, Duarte, California, United States
California Research Institute, Los Angeles, California, United States
University of California, San Francisco | HDFCCC - Hematopoietic Malignancies, San Francisco, California, United States
Yale Cancer Center, New Haven, Connecticut, United States
Johns Hopkins Medical Center, Baltimore, Maryland, United States
Maryland Oncology Hematology, P.A., Rockville, Maryland, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
University of Mississippi Medical Center, Jackson, Mississippi, United States
Weill Cornell Medicine, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Wake Forest Baptist Medical Center / Wake Forest University, Winston-Salem, North Carolina, United States
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
Providence Portland Medical Center, Portland, Oregon, United States
University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Texas Oncology - Austin Midtown, Austin, Texas, United States
Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
Texas Oncology - Northeast Texas, Tyler, Texas, United States
Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States
University of Alberta / Cross Cancer Institute, Edmonton, Alberta, Canada
University Health Network, Princess Margaret Hospital, Toronto, Other, Canada
Institut Gustave Roussy, Villejuif Cedex, Other, France
Istituto Europeo di Oncologia, Milano, Other, Italy
Policlinico Universitario Agostino Gemelli, Rome, Other, Italy
Hospital Universitari Vall d'Hebron, Barcelona, Other, Spain
L'Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Other, Spain
HM Centro Integral Oncologico Clara Campal, Madrid, Other, Spain
Sarah Cannon Research Institute UK, London, Other, United Kingdom
The Royal Marsden Hospital (Surrey), Sutton, Other, United Kingdom
Name: Andres Forero-Torres, MD
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR